Publication Cover
Inhalation Toxicology
International Forum for Respiratory Research
Volume 36, 2024 - Issue 3
45
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

Notoginsenoside R1 restrains the proliferation and migration of airway smooth muscle cells isolated from rats with chronic obstructive pulmonary disease

, , , , &
Pages 145-157 | Received 16 Oct 2023, Accepted 10 Feb 2024, Published online: 27 Feb 2024
 

Abstract

Objective

Chronic obstructive pulmonary disease (COPD) is a common disorder that is characterized by systemic and lung inflammation. Notoginsenoside R1 (NGR1) displays anti-inflammatory properties in numerous diseases. We aimed to explore the function and mechanism of NGR1 in COPD.

Materials and methods

COPD rats were established through cigarette smoke exposure, lipopolysaccharide injection, and cold stimulation. Rat airway smooth muscle cells (ASMCs) were separated and identified. Then, ASMCs were treated with NGR1 (25 or 50 μM) and cigarette smoke extract (CSE). Thereafter, the vitality, proliferation, and migration of ASMCs were measured. Additionally, cell cycle, inflammation-related factors, α-SMA, and PI3K/AKT pathway-related marker expressions of the ASMCs were also detected. Molecular docking experiments were conducted to explore the interaction of NGR1 to PI3K, TGF-β, p65, and AKT. Moreover, 740 Y-P (a PI3K/Akt pathway agonist) were used to validate the mechanism of NGR1 on COPD.

Results

NGR1 inhibited the proliferation and migration, but caused cell cycle arrest for CSE-triggered ASMCs. Furthermore, NGR1 not only decreased IL-1β, IL-6, IL-8, and TNF-α contents, but also reduced α-SMA expression in CSE-stimulated ASMCs. Moreover, NGR1restrainedTGF-β1 expression, PI3K, p65, and AKT phosphorylation in CSE-stimulated ASMCs. Molecular docking experiments showed NGR1 exhibited a strong binding ability to PI3K, TGF-β1, p65, and AKT. Notably, the effects of NGR1 on the proliferation and migration of CSE-induced ASMCs were reversed by 740 Y-P.

Conclusions

NGR1 can restrain the proliferation and migration of CSE-induced ASMCs, indicating that NGR1 may be a therapeutic candidate for treating COPD.

Disclosure statement

All authors declared there were no competing interests.

Author’s contribution

Conception and design of the research by Bin Wang and Yi Chen; Acquisition of data by Xiaoyong Li; Analysis and interpretation of data by Kai Chen and Xuefei Shi; Statistical analysis by Shunli Dong and Xuefei Shi; Xiaoyong Li drafted the manuscript, Xiaoyong Li and Yi Chen revised the manuscript.

Data availability statement

All data will be available upon request.

Additional information

Funding

This study was supported by the Public Technology Applied Research Program of Huzhou City under Grant [number 2020GY07] and Zhejiang Traditional Chinese Medicine Science and Technology Plan Project [number 2024ZL1020].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.